Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2007-04-12 20:05:47 UTC
Update Date2021-09-14 15:40:23 UTC
HMDB IDHMDB0006001
Secondary Accession Numbers
  • HMDB06001
Metabolite Identification
Common Name3'-Hydroxystanozolol
Description3'-Hydroxystanozolol is a metabolite of stanozolol. Stanozolol has the potential for misuse as an anabolic steroid in horse racing. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is a synthetic anabolic androgenic steroid often abused in sports to enhance performance. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattle's urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities.
Structure
Data?1582752370
Synonyms
ValueSource
17alpha-Methyl-17beta-hydroxy-5alpha-androstano(3,2-c)pyrazoleMeSH
3'-HydroxystanazololHMDB
(5 ,17 )-1',2'-dihydro-17-Hydroxy-17-methyl-5'H-androst-2-eno[3,2-c]pyrazol-5'-oneHMDB
3'-HydroxystanozololMeSH
Chemical FormulaC21H32N2O2
Average Molecular Weight344.491
Monoisotopic Molecular Weight344.246378278
IUPAC Name(1S,2S,10S,13R,14S,17S,18S)-17-hydroxy-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icos-4(8)-en-5-one
Traditional Name(1S,2S,10S,13R,14S,17S,18S)-17-hydroxy-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icos-4(8)-en-5-one
CAS Registry Number125709-39-9
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C(=O)NN3
InChI Identifier
InChI=1S/C21H32N2O2/c1-19-11-14-17(22-23-18(14)24)10-12(19)4-5-13-15(19)6-8-20(2)16(13)7-9-21(20,3)25/h12-13,15-16,25H,4-11H2,1-3H3,(H2,22,23,24)/t12-,13+,15-,16-,19-,20-,21-/m0/s1
InChI KeySWPAIUOYLTYQKK-YEZTZDHTSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrane steroids
Alternative Parents
Substituents
  • Estrane-skeleton
  • Hydroxysteroid
  • 17-hydroxysteroid
  • Pyrazolinone
  • Azole
  • Cyclic alcohol
  • Pyrazole
  • Tertiary alcohol
  • Vinylogous amide
  • Heteroaromatic compound
  • Lactam
  • Organoheterocyclic compound
  • Azacycle
  • Organopnictogen compound
  • Alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organic oxide
  • Organic nitrogen compound
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Process
Role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.0052 g/LALOGPS
logP2.3ALOGPS
logP2.5ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)11.51ChemAxon
pKa (Strongest Basic)2.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area61.36 ŲChemAxon
Rotatable Bond Count0ChemAxon
Refractivity109.13 m³·mol⁻¹ChemAxon
Polarizability40.07 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+179.78331661259
DarkChem[M-H]-177.85731661259
DeepCCS[M-2H]-210.57930932474
DeepCCS[M+Na]+184.89830932474
AllCCS[M+H]+185.632859911
AllCCS[M+H-H2O]+182.932859911
AllCCS[M+NH4]+188.132859911
AllCCS[M+Na]+188.832859911
AllCCS[M-H]-192.032859911
AllCCS[M+Na-2H]-192.232859911
AllCCS[M+HCOO]-192.632859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.5.86 minutes32390414
Predicted by Siyang on May 30, 202212.9254 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20221.95 minutes32390414
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid2055.9 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid247.2 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid192.0 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid160.9 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid337.9 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid529.8 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid502.9 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)129.2 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid1020.4 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid481.1 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid1120.3 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid359.0 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid423.9 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate257.2 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA343.9 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water7.9 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
3'-Hydroxystanozolol[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C(=O)NN33422.9Standard polar33892256
3'-Hydroxystanozolol[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C(=O)NN33129.9Standard non polar33892256
3'-Hydroxystanozolol[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C(=O)NN33492.8Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
3'-Hydroxystanozolol,1TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH][NH]C3=O3245.3Semi standard non polar33892256
3'-Hydroxystanozolol,1TMS,isomer #2C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)[NH]N([Si](C)(C)C)C3=O3199.8Semi standard non polar33892256
3'-Hydroxystanozolol,1TMS,isomer #3C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)[NH]C3=O3230.1Semi standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)[NH]C3=O3261.2Semi standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)[NH]C3=O3332.0Standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)[NH]C3=O3504.2Standard polar33892256
3'-Hydroxystanozolol,2TMS,isomer #2C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH]N([Si](C)(C)C)C3=O3246.7Semi standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #2C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH]N([Si](C)(C)C)C3=O3288.8Standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #2C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)[NH]N([Si](C)(C)C)C3=O3526.8Standard polar33892256
3'-Hydroxystanozolol,2TMS,isomer #3C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)N([Si](C)(C)C)C3=O3241.0Semi standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #3C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)N([Si](C)(C)C)C3=O3344.3Standard non polar33892256
3'-Hydroxystanozolol,2TMS,isomer #3C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O)N([Si](C)(C)C)N([Si](C)(C)C)C3=O3499.6Standard polar33892256
3'-Hydroxystanozolol,3TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N([Si](C)(C)C)C3=O3246.0Semi standard non polar33892256
3'-Hydroxystanozolol,3TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N([Si](C)(C)C)C3=O3299.7Standard non polar33892256
3'-Hydroxystanozolol,3TMS,isomer #1C[C@]12CC3=C(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O[Si](C)(C)C)N([Si](C)(C)C)N([Si](C)(C)C)C3=O3445.1Standard polar33892256
3'-Hydroxystanozolol,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH][NH]53480.1Semi standard non polar33892256
3'-Hydroxystanozolol,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N1[NH]C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C1=O3418.7Semi standard non polar33892256
3'-Hydroxystanozolol,1TBDMS,isomer #3CC(C)(C)[Si](C)(C)N1[NH]C(=O)C2=C1C[C@@H]1CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@@]1(C)C23431.7Semi standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH]N5[Si](C)(C)C(C)(C)C3679.2Semi standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH]N5[Si](C)(C)C(C)(C)C3860.7Standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)[NH]N5[Si](C)(C)C(C)(C)C3667.3Standard polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)[NH]53665.8Semi standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)[NH]53798.6Standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)[NH]53680.3Standard polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)N1C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C(=O)N1[Si](C)(C)C(C)(C)C3643.5Semi standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)N1C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C(=O)N1[Si](C)(C)C(C)(C)C3849.5Standard non polar33892256
3'-Hydroxystanozolol,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)N1C2=C(C[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@@]3(C)[C@H]4CC[C@]3(C)O)C2)C(=O)N1[Si](C)(C)C(C)(C)C3662.4Standard polar33892256
3'-Hydroxystanozolol,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)N5[Si](C)(C)C(C)(C)C3833.1Semi standard non polar33892256
3'-Hydroxystanozolol,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)N5[Si](C)(C)C(C)(C)C4021.3Standard non polar33892256
3'-Hydroxystanozolol,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@@]21C)C(=O)N([Si](C)(C)C(C)(C)C)N5[Si](C)(C)C(C)(C)C3666.0Standard polar33892256
Spectra
Biological Properties
Cellular Locations
  • Extracellular
  • Membrane
Biospecimen LocationsNot Available
Tissue LocationsNot Available
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDFDB023797
KNApSAcK IDNot Available
Chemspider ID30776569
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound14299601
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available